JP3762969B2 - 嚥下障害改善剤 - Google Patents
嚥下障害改善剤 Download PDFInfo
- Publication number
- JP3762969B2 JP3762969B2 JP2003097389A JP2003097389A JP3762969B2 JP 3762969 B2 JP3762969 B2 JP 3762969B2 JP 2003097389 A JP2003097389 A JP 2003097389A JP 2003097389 A JP2003097389 A JP 2003097389A JP 3762969 B2 JP3762969 B2 JP 3762969B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- essential oil
- black pepper
- dysphagia
- experiment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000019505 Deglutition disease Diseases 0.000 title claims description 19
- 239000000341 volatile oil Substances 0.000 claims description 31
- 244000203593 Piper nigrum Species 0.000 claims description 27
- 235000008184 Piper nigrum Nutrition 0.000 claims description 27
- 235000013614 black pepper Nutrition 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000002474 experimental method Methods 0.000 description 18
- 230000009747 swallowing Effects 0.000 description 17
- 230000011514 reflex Effects 0.000 description 14
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 12
- 102100024304 Protachykinin-1 Human genes 0.000 description 12
- 101800003906 Substance P Proteins 0.000 description 12
- 206010035664 Pneumonia Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 206010035669 Pneumonia aspiration Diseases 0.000 description 5
- 238000000222 aromatherapy Methods 0.000 description 5
- 201000009807 aspiration pneumonia Diseases 0.000 description 5
- 244000178870 Lavandula angustifolia Species 0.000 description 4
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000001102 lavandula vera Substances 0.000 description 4
- 235000018219 lavender Nutrition 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 210000004227 basal ganglia Anatomy 0.000 description 3
- 229960002504 capsaicin Drugs 0.000 description 3
- 235000017663 capsaicin Nutrition 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000001640 nerve ending Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000012033 vegetable salad Nutrition 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 125000003447 alpha-pinene group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- -1 terpene compounds Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003097389A JP3762969B2 (ja) | 2003-03-31 | 2003-03-31 | 嚥下障害改善剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003097389A JP3762969B2 (ja) | 2003-03-31 | 2003-03-31 | 嚥下障害改善剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004300103A JP2004300103A (ja) | 2004-10-28 |
| JP2004300103A5 JP2004300103A5 (enExample) | 2005-11-04 |
| JP3762969B2 true JP3762969B2 (ja) | 2006-04-05 |
Family
ID=33409190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003097389A Expired - Fee Related JP3762969B2 (ja) | 2003-03-31 | 2003-03-31 | 嚥下障害改善剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3762969B2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008044861A (ja) * | 2006-08-11 | 2008-02-28 | En Otsuka Pharmaceutical Co Ltd | 誤嚥性肺炎予防剤 |
| MX2012015231A (es) * | 2010-06-28 | 2013-01-28 | Nestec Sa | Metodos para la administracion de formulaciones para alimentacion por sonda. |
| CN108853093A (zh) | 2011-12-21 | 2018-11-23 | 明治制果药业株式会社 | 局部给药型的吞咽障碍改善用药物 |
| WO2014199486A1 (ja) | 2013-06-13 | 2014-12-18 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 嚥下障害改善用医薬品 |
| US9974768B2 (en) | 2013-06-13 | 2018-05-22 | Meiji Seika Pharma Co., Ltd. | Pharmaceutical for improving dysphagia |
| CN104758861A (zh) * | 2014-01-07 | 2015-07-08 | 王福廷 | 治疗噎膈病的药物 |
-
2003
- 2003-03-31 JP JP2003097389A patent/JP3762969B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004300103A (ja) | 2004-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6790465B2 (en) | Composition and method for treating snoring | |
| JP3762969B2 (ja) | 嚥下障害改善剤 | |
| Wongwiwatthananukit et al. | Efficacy of Vernonia cinerea for smoking cessation | |
| Dudhamal | Review of grey literature on Ayurveda wound healing formulations and procedures-A systematic review | |
| CN103735686B (zh) | 纾解忧郁、愉悦身心的芳香植物复方精油及其制备方法 | |
| CN1927160A (zh) | 漱口液及制备方法 | |
| ATE410163T1 (de) | Verfahren zur behandlung und diagnose von atemstörungen im schlaf mit zonisamid und mittel zur durchführung des verfahrens | |
| JP4889270B2 (ja) | 低栄養状態にある患者の食欲不振改善のための薬剤 | |
| Alayadi | The Impact of Nicotine Patches on Gingival and Oral Health: A Narrative Review | |
| Davis | Tobacco Cessation for the Dental Team: A Practical Guide Part 1: Background & Overview | |
| RU2532399C2 (ru) | Способ лечения пародонтита | |
| Bali et al. | Peppermint Aroma in Hospitals: A Scent-Sational Approach to Patient and Staff Well-Being | |
| Priya et al. | Bone one session treatment: A new concept of treating periodontal diseases | |
| JP2006282509A (ja) | 抑うつ気分の改善用組成物 | |
| Dhar et al. | Medicinal Plants of India | |
| RU2552307C1 (ru) | Способ лечения воспалительных заболеваний пародонта и слизистой оболочки полости рта | |
| Chen et al. | Intranasal administration of tissue inhibitor of metalloproteinase 1 extracted from stem cells from human exfoliated deciduous teeth-conditioned medium improves neurological outcomes and alpha-synuclein elimination in Parkinson's disease mice | |
| CN1589867A (zh) | 一种治疗急性脑血管疾病的药物及其制备方法 | |
| Gavirangaiah et al. | Efficacy of lycopene and serratiopeptidase in the management of oral submucous fibrosis: a placebo-controlled follow up study | |
| Pasula et al. | Oral Myiasis (Chrysomya Bezziana): Its Cause, Clinical Feature And Management. | |
| CN102018887B (zh) | 一种洁牙药物组合提取物及其功能卷烟 | |
| CN110464749A (zh) | 治疗鼻炎的外用中药药油 | |
| Syed et al. | Assessment of the Efficacy of Orally Administered Lycopene in Improving the Mean Maximum Incisal Opening in Individuals Suffering from Oral Submucous Fibrosis | |
| Pinheiro et al. | Evaluation of the effectiveness of different biomaterials used for the surgical repair of palatine wounds in gingival grafts | |
| Alaraby et al. | Locally delivered coconut oil in nonsurgical therapy of stage II and III grade B periodontitis: A randomized controlled clinical trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050708 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050708 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20050708 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050708 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20050901 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050913 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051107 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051129 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051220 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 3762969 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090127 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100127 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120127 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140127 Year of fee payment: 8 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |